Animals that cannot sense endotoxin may die if they are infected by Gram-negative bacteria. Animals that sense endotoxin and respond too vigorously may also die, victims of their own inflammatory reactions. The outcome of Gram-negative bacterial infection is thus determined not only by an individual's ability to sense endotoxin and respond to its presence, but also by numerous phenomena that inactivate endotoxin and/or prevent harmful reactions to it. Endotoxin sensing requires the MD-2/TLR4 recognition complex and occurs principally in local tissues and the liver. This review highlights the known detoxification mechanisms, which include: (i) proteins that facilitate LPS sequestration by plasma lipoproteins, prevent interactions between the bioactive lipid A moiety and MD-2/TLR4, or promote cellular uptake via non-signaling pathway(s); (ii) enzymes that deacylate or dephosphorylate lipid A; (iii) mechanisms that remove LPS and Gram-negative bacteria from the bloodstream; and (iv) neuroendocrine adaptations that modulate LPS-induced mediator production or neutralize pro-inflammatory molecules in the circulation. In general, the mechanisms for sensing and detoxifying endotoxin seem to be compartmentalized (local versus systemic), dynamic, and variable between individuals. They may have evolved to confine infection and inflammation to extravascular sites of infection while preventing harmful systemic reactions. Integration of endotoxin sensing and detoxification is essential for successful host defense.
INTRODUCTION
Unlike many protein exotoxins, Gram-negative bacterial endotoxin (lipopolysaccharide, or LPS) has no enzymatic or other intrinsic activity; the 'toxicity' of LPS is conferred entirely by the animal that senses its presence and reacts to it in injurious ways. When animals sense endotoxin, however, the usual outcome is a successful antimicrobial defense, not lethal toxicity. In adapting to a world filled with Gram-negative bacteria, animals evolved mechanisms that allow both rapid recognition of endotoxin, as one way to sense invading bacteria and mobilize host defenses, and endotoxin detoxification so as to avoid tissue injury.
There is now little doubt that endotoxin recognition plays an important role in antimicrobial host defense; animals that have disabling mutations in MD-2 or Toll-like receptor 4 (TLR4), which form the LPS signaling receptor complex, are susceptible to Gram-negative bacterial infections. 1 The significance of the body's endotoxin-detoxifying mechanisms is less well established. Here, I review these mechanisms and assess their contributions to the innate immune response to endotoxin and Gram-negative bacteria. After a brief description of the phenomena, I shall discuss their apparent functions in time and place, the evidence that the mechanisms are regulated in vivo, and the possible significance of endotoxin sensing and detoxification in humans. The review concludes with a discussion of some implications for therapy and further research.
ENDOTOXIN RECOGNITION
Recent evidence supports the activation scheme illustrated in Figure 1 . LPS, which is naturally present in bacterial membranes or membrane fragments, may be transferred produce TLR4 but not MD-2 may be activated by picomolar concentrations of LPS-MD-2 complexes. 3, 4 LPS-containing membranes and/or molecular aggregates may also be taken up by cells via a pathway that does not initiate the activation sequence; 2,5 this route may be favored in the presence of high concentrations of LBP. Endotoxin recognition has been discussed in several excellent recent reviews 2,6-9 and will not be described in detail here.
ENDOTOXIN DETOXIFICATION
The known endotoxin detoxification mechanisms may be grouped into four categories: (i) molecules that bind LPS and prevent it from engaging TLR4; (ii) enzymes that degrade the lipid A moiety in ways that decrease its activity; (iii) inactivation following uptake into the liver and spleen; and (iv) adaptations that modify target cell responses to LPS. As it is used here, the term 'detoxification' thus encompasses reversible (e.g. binding, sequestration) and irreversible (chemical) modifications of the LPS (lipid A) itself, as well as indirect mechanisms that neutralize or modulate pro-inflammatory host responses to LPS. Potential intracellular control mechanisms have been recently reviewed by Ulevitch. 7 
Physical sequestration of lipid A

Soluble proteins that bind LPS or lipid A
Numerous host proteins may bind LPS and prevent it from contacting MD-2/TLR4. They include collectins (mannose-binding lectin, surfactant proteins A and D 10 ), anti-endotoxin antibodies, bactericidal permeabilityincreasing protein (BPI; also known as CAP57), lactoferrin, 11 CAP18, 12 lysozyme, 13 and tissue factor pathway inhibitor. 14 For an excellent review of LPS-binding proteins, see Chaby. 15 Antibody-mediated LPS clearance. Specific antigenic exposure is not required for the production of natural antibodies, among which are many IgM and IgG antibodies that bind different LPSs. This broad range of binding specificities may help animals defend themselves from a diverse array of commensal and environmental Gram-negative bacteria. Indeed, these antibodies often bind LPS O-antigens rather than the more conserved, but less accessible, core or lipid A structures. 16 Although natural antibodies typically have low affinity for binding LPS and other antigens, there is evidence that they are important for protecting experimental animals from both endotoxin challenge 16 and septic peritonitis. 17 Complexes of IgM and LPS can activate the classical complement pathway. The C3-bearing complex is then removed from the circulation by binding to com-plement (CR1) receptors on erythrocytes or to CR3 on macrophages in the liver and spleen. 18 IgG antibodies that bind endotoxins are typically of the IgG 3 isotype (in humans, IgG 2 ); when they bind LPS in the circulation, they may clear it into the liver, spleen and other reticuloendothelial tissues. 19 Collectins. Mannose-binding lectin (MBL) binds sugars that have equatorial C3-OH and C4-OH groups and are separated by ~45 Å on microbial surfaces. 20 MBL may neutralize LPSs that bear these structures 21 by preventing them from binding MD-2/TLR4, by activating complement (C3) and promoting clearance as described above for IgM, or by binding calreticulin/CD91 C1q receptor complexes on macrophages. 10 Surfactant proteins A (SP-A) and D (SP-D) dampen inflammatory responses to LPS in several ways, most prominently by interfering with the interactions of LPS with CD14 and/or downstream molecules in the LPS recognition pathway. 10 LPS-binding neutrophil granule proteins. BPI, lactoferrin, lysozyme and CAP18 are all stored in neutrophil granules and released when the cells undergo phagocytosis or exocytosis. Each of these proteins has positivelycharged domain(s) that bind the negatively-charged lipid A moiety. The best-studied is BPI, a ~60 kDa azurophilic granule protein. 22, 23 As its name implies, BPI kills Gram-negative bacteria by disrupting the integrity of the bacterial cell wall. It binds lipid A with greater affinity than does LBP, which it closely resembles in structure. 24 BPI prevents LBP from transferring LPS to CD14, favoring the uptake of LPS aggregates by host monocytes and neutrophils in a way that avoids cell activation. 22 CAP18 is also a potent LPS inhibitor. 12, 25 Other granule proteins may enhance responses to LPS: azurocidin (CAP37, heparin-binding protein) binds LPS and augments LPS-induced TNF, IL-8 and prostaglandin E 2 (PGE 2 ) production by monocytes. 26 Plasma lipoproteins. When LPS is injected intravenously into experimental animals, many of the LPS molecules bind quickly to circulating lipoproteins and are slowly cleared from the circulation by tissues that express specific lipoprotein receptors. Lipoproteinbound LPS does not stimulate cells, suggesting that the lipid A moiety inserts into lipoprotein particles in such a way that it is no longer exposed. Transfer of LPS from bacterial membranes to lipoproteins is promoted by certain plasma proteins, including phospholipid transfer protein and, especially, LBP. 27 LPS binding to different lipoprotein species correlates with the lipoprotein's content of phospholipid, which is found on the particle surface. 28, 29 The ultimate fate of the LPS-lipoprotein particle is determined largely by its apolipoprotein content, however; particles that contain apoA-1 bind to SR-B1 receptors on various cells, whereas apoE-rich particles are more likely to be taken up via the LDL receptor or lipoprotein receptor-related protein (LRP) VLDL receptor on hepatocytes. ApoE -/mice are more susceptible to LPS-induced lethality than are normal mice; infusion of chylomicrons or VLDL, which contain apoE, can protect experimental animals from LPS challenge. [30] [31] [32] One plausible protective mechanism is suggested by apoE's ability to deliver LPS to hepatocytes, 33 bypassing cytokine-producing Kupffer cells and inducing tolerance in the liver. 34 Infusing HDL has also been protective in some animal models. 35 When LPS binds to monocytes in the presence of 90% human serum, approximately 20% of it is quickly internalized whereas the remainder is released ('effluxed') from the cell surface over an hour or so. sCD14 in the serum transfers most of the released LPS to lipoproteins. 36, 37 Increasing the rate of LPS efflux by adding sCD14 decreases the cells' production of TNF and IL-8, suggesting that LPS efflux may be a mechanism by which cellular responses to LPS are limited in vivo.
Enzymatic degradation of lipid A
The MD2/TLR4 signalling complex recognizes the most highly conserved structural domain of LPS, lipid A. Studies of natural and synthetic lipid A analogs showed that two features of lipid A are required for full recognition by animal cells: there must be phosphates at positions 1 and 4′ and two acyloxyacyl linkages ( Fig. 2 ). There is evidence that both deacylation and dephosphorylation of LPS occur in vivo.
Deacylation
Vertebrates possess an enzyme, acyloxyacyl hydrolase (AOAH), that selectively removes the secondary or 'piggyback' fatty acyl chains from the lipid A moiety of LPSs. 38 This reaction leaves 3-hydroxy fatty acyl chains attached to the lipid A backbone, producing a tetra-acyl lipid A moiety that binds MD-2/TLR4 but either does not initiate a signal (human cells) or is a partial agonist (rodent cells). 39 AOAH is found in myeloid cells (dendritic cells, monocyte-macrophages, neutrophils) and in renal cortical tubule cells. Although it seems to function principally to deacylate LPS that has been internalized by cells, it may also be active in extracellular fluids, especially in inflammatory exudates 40 and the urine. 41 Intracellular deacylation does not influence the ability of the deacylating cell to respond to LPS. On the other hand, studies in mice that do not produce the enzyme indicate that LPS deacylation is important for limiting the duration of illness as well as the antibody response to Gram-negative bacterial infection (M. Lu et al., unpublished observations).
Dephosphorylation
Although there is evidence for both extracellular and intracellular dephosphorylation of LPS, its significance is uncertain. Peterson et al. 42 found that murine macrophages can remove phosphates from a deep rough LPS; the phosphatase was most active at an acid pH and was tartrateresistant. Hampton et al. 43 reported that macrophages can remove the phosphate at the 1′ position of lipid IVa, the tetra-acyl lipid A precursor, and that this reaction can be enhanced by prior exposure to LPS. At the present time, it is uncertain that dephosphorylation plays an important role in LPS detoxification in vivo. On the other hand, investigators in The Netherlands have found that administering alkaline phosphatase can protect animals from LPS challenge. [44] [45] [46] [47] Much remains to be learned about the latter observation, including the site(s) on lipid A that undergo dephosphorylation by alkaline phosphatases in vivo and the enzyme's ability to act on LPSs from diverse Gramnegative bacteria. Detoxification by phosphatases might be limited to LPSs in which the lipid A phosphates are not substituted with sugars, ethanolamine, or other groups. 48
Inactivation by the reticulo-endothelial system
In rodents or rabbits, the liver quickly removes as much as 40-50% of an intravenous dose of LPS from the bloodstream. [49] [50] [51] Most of the available evidence suggests that it is initially taken up by Kupffer cells and then moves into hepatocytes. 50, 52 Intact Gram-negative bacteria are even more completely removed from the circulation by the liver and, to a lesser extent, the spleen. 53, 54 Several maneuvers that interfere with macrophage function in vivo ('reticulo-endothelial blockade') can greatly increase endotoxin-induced lethality in experimental animals. 55 Hepatic uptake and detoxification thus seem There is evidence that the hepatic sinusoids are perfused, more or less continuously, with endotoxin-laden blood from the GI tract, 56, 57 and that the liver effectively filters this endotoxin from the bloodstream without reacting to it. The absence of hepatic inflammation may reflect the rapid, selective release of IL-10 and/or PGE 2 by LPS-stimulated sinusoidal cells. 58, 59 A fraction of the portal blood LPS may also be taken up by scavenger receptors and enter a nonactivating intracellular pathway in Kupffer cells, sinusoidal endothelial cells, or both. Given its evident importance, it is surprising that little is known about how the liver detoxifies endotoxin. Several studies have found that LPS deacylation occurs in the liver, 51,60-62 but the biological significance of this reaction is not known.
Modulation of target cell response mechanisms
Cells that have been exposed to low concentrations of LPS typically undergo a series of adaptations that alter their responses to a second exposure. Although the molecular basis for this 'acute endotoxin tolerance' is not well understood, recent studies point to an intracellular phosphatase, SHIP, as a necessary intermediate. 63 When tolerant cells sense LPS a second time, some responses may increase (e.g. the production of IL-1Ra), while others decrease (TNF, IL-6, and IL-1β production). There is also 'cross-tolerance', since LPS can induce tolerance to other agonists (e.g. Staphylococcus aureus cells and toxic shock syndrome toxin-1), and other stimuli can induce tolerance to LPS. 64 Tolerance to the fever-inducing ability of LPS has been noted in humans recovering from typhoid fever, pyelonephritis, and malaria. 64 Cells exposed to LPS typically produce (early) proinflammatory (TNF, IL-1β) and (late) anti-inflammatory (IL-6, IL-10, IL-1Ra) mediators. Environmental influences can modulate these responses. In the most straightforward example of this phenomenon, low concentrations of epinephrine, PGE 2 , or histamine can greatly diminish the ability of monocytes to produce TNF in response to LPS. 65, 66 Remarkably, these treatments either maintain or increase LPS-elicited production of IL-10 and IL-1Ra, suggesting that they induce a 'reprogramming' of the cellular machinery so as to decrease pro-inflammatory cytokine production while increasing or maintaining the output of anti-inflammatory molecules.
In some circumstances, cells may also be 'primed' by interferon-γ (IFN-γ) or other stimuli to respond more vigorously to endotoxin exposure. Although there is no definite clinical example of this phenomenon, it most closely resembles the proposed 'two-hit' series in which patients experience a lethal response to infection after having been 'primed' by previous infection or another injurious event. 67
The concentration-dependent effects of LBP, CD14, and MD-2
It is noteworthy that the three key extracellular molecules in the LPS activation sequence can also inhibit LPS recognition by cells. The evidence comes largely from studies performed either in vitro or in rodents. Nonetheless, in each case, activation occurs at low concentrations (presumably, those likely to be found in tissues) and inhibition at high (plasma) concentrations. At low levels, for instance, LBP catalyzes the transfer of LPS monomers to CD14, whereas at high concentrations it promotes the clearance of LPS aggregates via a non-activating cellular pathway 5, 22, 68 and may interfere with LPS transfer from mCD14 to MD-2. 69 Studies in LBP knockout mice suggest that LBP has an important role in mobilizing pro-inflammatory host defenses in extravascular spaces, such as the peritoneal cavity, 70-72 but probably not in the bloodstream. 73 Administering a large intraperitoneal dose of recombinant LBP protected mice from Escherichia coli peritonitis and from i.p. LPS injection. 74 In LBP-sufficient wild-type mice, administering anti-LBP antibodies prior to intravenous infection with a high inoculum of Klebsiella pneumoniae was associated with plasma TNF levels that exceeded those in infected control mice, 75 in keeping with observations that plasma LBP can inhibit LPS activation of monocytes. 76 Soluble CD14, which can deliver LPS to enable cell activation via MD-2/TLR4, can also inhibit LPSinduced cytokine production in whole blood ex vivo 36, 77 and LPS priming of neutrophils in vitro. 78 Support for an inhibitory role for sCD14 also comes from two in vivo observations: administering recombinant sCD14 can prevent mortality in mice challenged with endotoxin, 79 as can overexpressing sCD14 in transgenic animals. 80 Although the inhibitory mechanism is uncertain, sCD14 promotes LPS efflux from monocytes and diminishes monocyte cytokine production in a dose-dependent fashion. 36 sCD14 thus has the ability to shuttle LPS to cells that express MD-2/TLR4 and from cells that have cellsurface LPS. The activation mechanism may predominate in extravascular spaces, where sCD14 can be produced by leukocytes and contribute to the inflammatory response (to both LPS and non-LPS ligands), 81, 82 while the inactivation role may be more important in the bloodstream. Although sCD14-LPS complexes can activate vascular endothelial cells in vitro, endothelial activation by LPS-sCD14 complexes seems to be much less robust than is activation via cytokines released from LPS-stimulated monocytes. 83 Although the normal plasma concentration of MD-2 has not been reported, adding recombinant soluble MD-2 to whole blood inhibits LPS-induced cytokine production. 84 MD-2 binds LPS tightly and does not transfer it readily to other proteins; when the available target cells already express MD-2/TLR4, soluble MD-2 may bind LPS and prevent it from interacting with these cells. In contrast, soluble MD-2 may deliver LPS to cells that express TLR4 but not MD-2; 85 epithelial and endothelial cells may be activated in this way. Pugin et al. 86 have recently suggested that MD-2, when it moves from the blood into extravascular tissues, may contribute to organ inflammation during sepsis.
Other host defense molecules can also have concentration-dependent activities. For example, low concentrations of MBL enhanced IL-6 and IL-8 secretion by monocytes incubated in vitro with Neisseria meningitidis, whereas high concentrations were inhibitory. 87 Normal concentrations of cortisol are permissive for acute phase protein synthesis whereas higher concentrations within the physiological range can be suppressive (inhibiting cytokine and acute phase protein production) or stimulatory (increasing IL-10 production). 88
TIME AND PLACE
Endotoxin sensing and detoxification in local and systemic compartments is summarized in Table 1 .
Endotoxin sensing is compartmentalized
Campisi et al. 89 recently reported that rats inoculated subcutaneously with E. coli develop fever and hypercorticosteronemia before it is possible to measure endotoxin or increased cytokine levels in the blood. They concluded that these systemic responses were evoked by a neural pathway from the periphery to the brain. Ross et al. 90 reached the same conclusion when a local anesthetic drug was able to block febrile responses to low doses of LPS injected into subcutaneous chambers in guinea pigs. The afferent pathways that mediate this communication from the periphery to the CNS are unknown, although nociceptive C-fibers may be most likely. 91 When endotoxin and/or IL-1β/TNF do enter the blood from an infected local site, they undergo enormous dilution. The initially low blood concentrations are sensed principally within the liver, from which vagal afferents transmit this information to the CNS. 92 Higher concentrations seem to be able to activate the hypothalamus directly. 93 At least in rodents, the 'news' of a local Gram-negative bacterial infection is thus communicated to the CNS when endotoxin sensing occurs in local tissue sites (where the highest endotoxin concentrations presumably occur), in the liver (low blood endotoxin concentrations), and possibly also in the brain (higher blood concentrations). Since infection usually begins within an extravascular tissue space and extends into the bloodstream only if local defenses fail, this compartmen-talization seems to graduate endotoxin recognition by the brain according to the severity of infection. As will be discussed below, endotoxin detoxification mechanisms also may be organized in a compartmental fashion, with the CNS playing a prominent role in modulating both local and systemic responses to LPS.
Endotoxin detoxification: local tissue sites of infection
Microbes enter tissues by crossing epithelial barriers. Tissue-resident phagocytes monitor the subepithelial spaces, sensing the presence of invading microbes and mobilizing inflammatory responses to eliminate them. Endotoxin sensing is, first and foremost, a local tissue phenomenon, and the initial local responses to endotoxin are pro-inflammatory. In addition, increased vascular permeability may allow sCD14, LBP, MBL and other LPS-sensing molecules to move into tissue spaces and augment these responses. 81, 94 Other features of the local response probably limit endotoxin recognition, however. Within minutes to hours, an influx of neutrophils brings supplies of BPI, lactoferrin and other neutrophil granule proteins that, when released into interstitial spaces, can bind extracellular LPS and prevent it from engaging MD-2/TLR4. Another neutrophil protein, azurocidin (CAP37), binds LPS and enhances its ability to stimulate monocytes to release both pro-inflammatory cytokines (TNF, IL-8) and PGE 2 . 26 Azurocidin is then thought to co-operate with prostanoids to increase capillary permeability, 95 which in turn allows immunoglobulins, complement and MBL to enter the infected site, where they may opsonize LPS for uptake by phagocytes. 22 Cathepsin G released from neutrophils may strip mCD14 from the surfaces of monocytes, reducing LPS sensing by these cells. 96 Adenosine, adenine nucleotides, superoxide dismutase and other molecules released by stimulated cells also may diminish local responses to LPS. 97, 98 Experimental animals typically require many hours (24-48 h) to develop 'tolerance' to endotoxin. Although enzymatic deacylation of LPS by phagocytes cultured in vitro also occurs relatively slowly, taking two or three days to reach completion, Weinrauch et al. 40 found that soluble constituents of an inflammatory exudate could greatly enhance the rate at which monocytes deacylate LPS. Enzymatic degradation may thus proceed more rapidly in local infection sites.
Endotoxin detoxification: the systemic compartment
The systemic compartment includes the bloodstream, the reticulo-endothelial system, and other organs distant from a local tissue site of infection. For this discussion, the two major elements of the compartment are the circulating blood and the reticulo-endothelial system.
Bloodstream (see Fig. 1B ) When Roth and Levin added radiolabeled LPS to anticoagulated whole human blood, less than 5% of the label bound to cells. 99 Although this low-level interaction is usually sufficient to elicit the production of TNF and other mediators in whole blood studied ex vivo, there is evidence that direct stimulation of blood cells probably accounts for very little of endotoxin's ability to elicit the pro-inflammatory mediators that appear in the blood in vivo. 100 In fact, it has been known for many years that the blood has numerous endotoxin detoxification mechanisms. Normal human serum neutralizes the ability of LPS to activate Limulus lysate, 101, 102 to kill mice, 103 and to stimulate human monocytes. 104 Endotoxin that enters the blood may be detoxified by binding to plasma lipoproteins; binding to natural antibodies, circulating MD-2 84 or soluble CD14; 36 inhibition by high levels of LBP; 76 and rapid efflux from CD14-expressing cells. 36, 37 As will be discussed below, there is evidence that all of these phenomena are more active in the blood of stressed individuals.
Reticulo-endothelial organs
The liver and spleen, the major filters for removing micro-organisms and endotoxin from the blood, also produce 0.25 to 0.5 of the TNF that appears in the human bloodstream following an intravenous injection of LPS. 105 Spek et al. 100 found that administering an anti-CD14 antibody prior to an intravenous bolus of LPS strongly inhibited pro-inflammatory cytokine release in volunteers, whereas the production of anti-inflammatory molecules (soluble TNF receptor type I, IL-1 receptor antagonist) was delayed but not significantly blunted. After comparing cytokine mRNA levels in peripheral blood cells with the cytokine protein levels measured in plasma, these authors concluded that 'peripheral blood cells are of negligible importance in LPS-induced production of inflammatory mediators in vivo'. The anti-CD14 antibody probably blocked pro-inflammatory cytokine production by preventing or delaying LPS activation of cells in the liver, not the circulating blood.
The systemic response to bloodborne endotoxin may thus be substantially mediated by Kupffer cells, although hepatic sinusoidal endothelial cells, dendritic cells and stellate cells can also respond to LPS by producing cytokines. 58 The spleen's contribution to the overall response is less certain. 106 Whereas the hepatic sinusoidal endotoxin sensors seem to ignore low levels of endotoxin in portal blood, there is evidently a concentration threshold for vigorous responses. Even above this threshold, LPS-induced production of TNF and IL-10 can be profoundly altered by catecholamines, cortisol, and other regulatory hormones that normally modulate cytokine production in the splanchnic bed. In rodents, for example, vagal efferents can dampen LPS-induced TNF production by releasing acetylcholine, which engages inhibitory α 7 -nicotinic receptors on macrophages. 107 The autonomic innervation of the rodent liver differs substantially from that of many other mammals, including humans, and the applicability of this finding to higher animals is uncertain. Nonetheless, it seems likely that systemic cytokine and metabolic responses to infection are both regulated by the autonomic nervous system's actions on the liver.
To summarize the simplest scenario: in infected extravascular tissues, LPS recognition is essential for mobilizing local defenses and for notifying the CNS that infection has occurred. Molecules that detoxify LPS appear in the local site as the inflammatory response ensues. Endotoxin sensing is thus followed over time by detoxification. In the systemic compartment, in contrast, many constitutive detoxification mechanisms normally help prevent inflammatory responses to circulating endotoxin. In general, activation of local innate anti-bacterial defenses is accompanied by systemic mechanisms that support local defenses yet seem to prevent harmful reactions in the bloodstream and in uninfected organs. 108 The liver serves the systemic compartment as its major endotoxin filter, sensor, and response mediator.
PERSON
Environmental (infection, disease, stress) and genetic influences
In general, adaptations to stress are regulated by the hypothalamus and brain stem (activation of the HPA, sympathetic and parasympathetic outflow) and the liver (acute phase reactions). In experimental animals, sensing via C-fibers may activate the HPA and diminish neutrophil-endothelial adhesion, thus promoting an antiinflammatory systemic environment. 109, 110 Activation of acute phase responses may also occur early in infection and other stresses. Whereas acute phase proteins such as LBP, mannose-binding lectin, 21 and C-reactive protein 111 may bind LPS and prevent it from directly activating cells, other acute phase reactants neutralize proteases, oxidants, and pro-inflammatory mediators that appear in the bloodstream. 108, 112 The blood levels of soluble TNF receptors and IL-1Ra greatly exceed those of TNF and IL-1, for instance, as do concentrations of the IL-1 type II decoy receptor. 113 Reduced cytokine responses to LPS have been noted in ex vivo studies of blood from patients with a mild, localized infection (appendicitis) 114 as well as in the blood of individuals experiencing non-infectious stresses. 115 Patients with localized infections also may have elevated plasma levels of anti-inflammatory cytokines (IL-10, IL-4) and reduced pro-inflammatory ones (IL-12), 114 even in the absence of systemic signs (fever or leukocytosis). AOAH mRNA and enzymatic activity increase in mouse liver and lung following endotoxin challenge 116 and in LPS-treated murine dendritic cells ex vivo. 117 With more severe illness, these changes become even more prominent. LPS binds more readily to lipoproteins in the plasma of severely septic patients than it does in plasma from normal volunteers, despite dramatic changes in lipoprotein distribution. 29 Levels of BPI, 118 LBP, 118 and sCD14 36 -all of which seem to contribute to LPS neutralization in the blood -may be elevated manyfold in the blood of septic patients, and the blood concentrations of catecholamines, cortisol, PGE 2 , and other modulatory molecules also increase. Infection is not required to induce these changes. In patients who survived cardiac arrest, for example, Adrie et al. 119 found that both plasma and cells contributed to 'immunosuppressive' responses when endotoxin was added to whole blood ex vivo. These findings are similar to those reported by several groups who studied the blood of patients with severe sepsis. 120, 121 The ability of IL-1 and TNF to activate reporter cells in vitro may also be greatly reduced in plasma from septic patients. 122 The inhibition of LPS-induced TNF production observed in these studies has been relative, not absolute. It remains possible that endotoxin may escape neutralization and have pro-inflammatory effects in the blood of sick patients. It seems most likely that this occurs in patients with overwhelming intravascular infection, such as fulminant meningococcemia (see below).
There is probably a spectrum of individual reactions to circulating endotoxin, much as there is great individual variability in responses to other stresses. When blood from large numbers of human subjects has been studied ex vivo, for example, the response to LPS exposure has varied many-fold. Although much of the variability in endotoxin sensitivity may reside in genes involved in LPS sensing, such as TLR4, [123] [124] [125] many genes that may contribute to endotoxin clearance are also polymorphic and some have been linked to the risk of developing severe sepsis. 126, 127 Accurate assessment of these gene-risk associations will require analyses of larger populations of individuals with diverse genetic backgrounds. Underlying disease states, psychological stresses, and other factors doubtless add to the heterogeneity observed in vivo.
Human responses to endotoxin
Volunteer endotoxemia
For understanding human responses to endotoxin in vivo, the most popular experimental model has involved injecting a standard intravenous bolus (3-4 ng/kg) of LPS into healthy volunteers. The reproducibility with which this stimulus elicits symptoms and signs raises an obvious question: if the systemic compartment has such effective mechanisms for inhibiting LPS signaling, how is it possible for small intravenous doses of LPS to induce pro-inflammatory responses?
The most obvious answer is that even these small amounts of endotoxin may exceed the capacity of the normal detoxification mechanisms in the circulating blood. In addition, the detoxification mechanisms that exist in blood may be unable to prevent endotoxin sensing in the splanchnic bed.
The intravenous endotoxin infusion model falls short in two significant ways, however. First, the infused subjects have almost always been healthy. The systemic reactions to bloodborne endotoxin that occur in healthy individuals may be different from those that occur in subjects whose endotoxin-detoxifying mechanisms have increased in response to injury or infection. If a brief infusion of epinephrine or cortisol can dramatically decrease LPS-induced TNF production in volunteers, 65, 128 it seems likely that systemic reactions to LPS are sensitively modulated in response to stress. Indeed, the febrile response to LPS is almost twice as great if LPS is infused in the evening, when circulating glucocorticoid levels are at their circadian nadir, than during the morning apex of blood cortisol concentration. 129 A second important point is that a bolus injection of LPS does not mimic the intermittent release of small amounts of endotoxin (or small numbers of bacteria) into the bloodstream from a tissue site of uncontrolled infection. In a 70 kg human, a 4 ng/kg i.v. bolus dose would produce a theoretical maximal endotoxin concentration of 60 pg/ml. Although much higher levels have been reported in septic human patients, 130, 131 it is not known with certainty that the endotoxin detected in plasma using the Limulus lysate assay is bioactive in vivo (since inhibitors must be removed prior to performing the test 101 ) or that its quantitation is accurate. 132 (A newer assay, based on immunodetection of lipid A, may also detect active or inactive molecules 133 .) The infused LPS, in contrast, has a certifiable weight-based potency. 134 Moreover, the Limulus-positive material found in septic patients probably enters the blood slowly over time, rather than abruptly as a bolus injection; 135 the kinetics of endotoxin inactivation may be quite different in the two situations.
Of all the diseases caused by Gram-negative bacteria, volunteer endotoxemia most closely mimics fulminant meningococcemia. In this uncommon disease, N. meningitidis colonizes the nasopharynx of healthy individuals, invades the bloodstream, infects vascular endothelial cells and releases large amounts of endotoxin (probably in outer membrane blebs 136 ). The highest reported plasma endotoxin levels have been measured in patients with meningococcemia. 137 The normal endotoxin-detoxifying forces in the systemic compartment are probably unable to deal with so much endotoxin, appearing in the bloodstream over a short period of time. On the other hand, there is evidence for significant endotoxin neutralization despite these high blood levels. In a seminal clinical study, Brantzaeg et al. 120 found that the stimulatory activity of meningococcal endotoxin in patients' plasma was demonstrable only if IL-10 were adsorbed from the plasma prior to adding it to reporter cells. It thus seems that the endotoxin that circulates in patients with fulminant meningococcemia is potentially stimulatory (i.e. not neutralized by lipoprotein binding, etc.) but that the systemic anti-inflammatory response may prevent or neutralize pro-inflammatory responses to it. Even in fulminant meningococcemia, the true significance of circulating endotoxin is thus not certain.
Hypersensitivity to endotoxin
One phenomenon not encompassed by the mechanisms discussed so far is the occurrence of heightened reactions to endotoxin in certain clinical and experimental situations. For instance, patients with typhoid fever, 138 tularemia, 138 and brucellosis 139 may have exaggerated febrile responses to an intravenous bolus of endotoxin. The basis for this hyper-reactivity is not fully understood. From their studies of experimental infection in humans, Greisman et al. 140, 141 concluded that patients with typhoid fever develop endotoxin tolerance in hepatic macrophages, that circulating endotoxin does not cause fever, and that endotoxin hyper-reactivity occurs only in extrahepatic sites. In particular, they found that patients with typhoid fever have exaggerated local inflammatory responses to intradermal (i.e. extravascular) injections of LPS. 138 In more recent studies of typhoid patients, House et al. 142 found lower than normal ex vivo cytokine responses in whole blood stimulated with LPS, particularly in the sicker subjects. Although the Greisman et al. 140, 141 and House et al. 142 findings are thus consistent with the general notion that responses to endotoxin are compartmentalized, so that extravascular reactions to endotoxin may occur whereas intravascular responses are inhibited, obviously much remains to be understood. In particular, what produces the state of endotoxin hypersensitivity, even if it is confined to extravascular sites? Clues have come from studies in which IFN-γ seems to be an essential mediator. 143 Although it has also been suggested that latent infections with Gram-negative bacteria may sensitize ('prime') animals to endotoxin, 144 no convincing clinical examples of endotoxin hypersensitivity have been recognized to date.
Other dramatic reactions to endotoxin include the dermal and generalized Shwartzman reactions (SR), in which a low priming dose prepares animals for greatly enhanced inflammatory responses to a second dose administered after a precisely delimited time interval. The SR are now thought to involve the activation of endothelial adhesion molecules by the initial (dermal or i.v.) stimulus, so that the cytokinemia that follows the intravenous dose provokes microvascular injury by neutrophil-platelet thrombi. Molecules that can substitute for LPS as the priming agent include IL-12 and IFN-γ. 145 In primed animals, the reactions can be provoked by intravenously administering LPS or a combination of IL-1β and TNF. 145 IL-10 may prevent the priming step. The reactions may also be prevented by administering heparin or by neutrophil or platelet depletion. Moreover, the generalized SR does not occur in adrenalectomized animals unless norepinephrine is administered, 146 αadrenergic blockade may be protective, and norepinephrine infusion exacerbates the lesions. It thus seems likely that coagulopathy and vasoconstriction are important factors in these dramatic reactions.
Although studies on the Shwartzman reactions have revealed much about the pathogenesis of inflammationinduced microthrombotic lesions, they have no definite clinical correlates, with the exception that vasoconstriction also contributes to sepsis-induced thrombosis of mid-sized vessels. 147 Even the equally impressive lesions of fulminant meningococcemia do not have the same pathology. 148
IMPLICATIONS FOR THERAPY
Targeting endotoxin in the systemic compartment
Climaxing a long and often heated debate over the protective properties of anti-lipid A or anti-core antibodies, 149 clinical trials in the early 1990s tested two IgM anti-endotoxin monoclonal antibodies for their ability to improve the survival of patients with Gram-negative bacterial sepsis. In retrospect, the failure of at least one of these drugs, HA-1A, might have been anticipated: it had low affinity for lipid A and significant cross-reactive binding toward B lymphocytes and the i-antigen on erythrocytes. 150 In other words, it was a 'natural' IgM antibody, with typically polyreactive, low-affinity binding. It may have been somewhat beneficial for patients with Gram-negative bacterial infections yet it was probably harmful to those with Gram-positive infections. 151 The other anti-endotoxin mAb, E5, had higher affinity for binding lipid A 152 but it also did not reproducibly improve survival of patients with severe sepsis. Antibodies to the O-polysaccharide chain are more effective for both prevention and therapy of Gram-negative infection in animals, but their narrow specificity limits their clinical usefulness. In a small clinical trial, infusion of IgM-rich immunoglobulin preparations was associated with a significant reduction in mortality from neonatal sepsis; 153 this result has not been confirmed and it is uncertain that endotoxin neutralization played an important role in the reported outcome.
The poor performance of the anti-endotoxin antibodies raises a general question. If the circulating blood and liver already have numerous mechanisms for detoxifying endotoxin, and if those mechanisms become more active as the body responds to infection, is it likely that infusing an additional endotoxin-neutralizing drug will benefit septic patients? Although several authors have found that patients with detectable plasma endotoxin are more likely to develop severe sepsis or die, and even more have found positive associations between plasma endotoxin and various other pathologies, it is uncertain that neutralizing this endotoxin would be beneficial. Moreover, as Hurley and Levin 154 commented in their meta-analysis of 14 published clinical studies of plasma endotoxin levels: 'the detection of endotoxin in isolation had no prognostic value…This is an unexpected finding, given the presumption that endotoxin is a critical mediator of Gram-negative sepsis'. Similar conclusions were reached by Bates et al. 155 in a large study of patients with sepsis syndrome and by Hurley 156 in a more recent meta-analysis. Very few of the patients in these studies had high-level endotoxemia, however, and it is in such patients that anti-endotoxin therapies might be most effective. This proposition was tested in a clinical trial of recombinant BPI treatment for fulminant meningococcemia. Although the long time interval between onset of illness and the administration of BPI precluded accurate assessment of its efficacy, the fact that the children who received the drug had fewer morbid events (amputated limbs) suggested that there was a therapeutic benefit. 157 Whether agents that detoxify circulating endotoxin can be beneficial in other clinical settings is an open question.
If important systemic inflammatory responses to bloodborne endotoxin arise in the liver, reducing hepatic endotoxin sensing might also be a worthwhile clinical goal. In addition to neutralizing endotoxin before it reaches the liver (for example, by administering BPI, MD-2 or lipoproteins) or interfering with its ability to stimulate hepatic sinusoidal cells (the presumed mechanism of an anti-CD14 antibody (100), an inhibitory lipid A analog, E5564, 158 and possibly of alkaline phosphatases 46, 47 ) , it might be possible to modulate cytokine production in the systemic compartment through neuroendocrine mechanisms. Although this notion is theoretically attractive, tachyphylaxis may quickly diminish catecholamines' ability to modulate LPS-induced cytokine production, 65, 159 clinical recognition of sepsis often occurs many hours after the early mediators have acted, and the impact of glucocorticoid administration may be unpredictable. 128 (Although there is growing support for prolonged, low-dose glucocorticoid therapy for patients with septic shock, regardless of its etiology, 160 whether the dramatic effects of glucocorticoids on cytokine levels reflect an action on the liver is uncertain. 161 ) It is also possible that augmenting vagus-mediated suppression of LPS-induced TNF production will be useful in humans. 107 In general, interventions that interfere with late-appearing downstream mediators, such as HMGB-1, 162 currently seem more likely to benefit septic patients.
Targeting endotoxin in local tissues
As with all other therapies intended to prevent unwanted inflammation by interfering with innate immune responses to infection, there is a potential pitfall: it is possible that enhancing endotoxin detoxification mechanisms in local tissues will interfere with the protective role of endotoxin sensing in host defense. On the other hand, recent studies have suggested that uncontrolled inflammation within infected extravascular tissues is the key factor in the pathogenesis of severe sepsis and septic shock; in these studies, circulating bacteria did not precipitate shock or systemic injury. 163, 164 These observations raise the possibility that low-level endotoxemia or bacteremia is usually a marker for unchecked infection and inflammation in an extravascular tissue site, not an independent stimulus to systemic inflammation. If this notion is correct, it is possible that enhancing endotoxindetoxifying mechanisms within infected tissues would benefit patients with Gram-negative infections, whether or not endotoxemia is detected. Small molecule inhibitors would seem most attractive for this purpose; one candidate lipid A antagonist, E5564, potently inhibits virtually all measured responses to experimental endotoxemia in humans 158 and is currently in clinical trials; it might be effective at local sites of infection. It is also conceivable that administering lipoproteins (or a phospholipid [phosphatidylcholine] emulsion 165 ) could neutralize endotoxin within infected sites, since lipoproteins move into extravascular tissue spaces, 166 as do the transfer proteins that promote LPS-lipoprotein binding. Choosing the optimal phospholipid may be important, however, since the phospholipid composition of lipoprotein particles changes during transit from blood to interstitial spaces; 166 in particular, phosphatidylcholine is lost, probably due to hydrolysis by lipoprotein lipase.
DIRECTIONS FOR FUTURE RESEARCH
We know very little about how LPS is released from bacteria within infected tissues, how it interacts with other molecules in interstitial spaces, and how it moves into the circulation. How much do the other molecules in the bacterial membrane influence host responses to endo-toxin? Does LPS directly stimulate sensory nerves, or does this require mediators released from activated phagocytes? What are the systemic consequences of this communication in humans, and how might they be controlled to prevent untoward outcomes? Although I have suggested a hypothetical version of endotoxin's behavior within local tissues, when and where endotoxin is actually neutralized by neutrophil-derived proteins and other factors are also not known. Can drugs enhance LPS detoxification in tissues?
Many of today's controversies about the extent to which LPS is detoxified in the bloodstream might be resolved if there were sensitive, specific assays for bioactive (stimulatory in vivo) endotoxin in plasma. Determining the physical state of endotoxin in plasma may also be revealing, since the binding partner(s) of the endotoxin that circulates 'free' in plasma (not bound to lipoproteins) are not known 15 -is the LPS that activates cells in hepatic sinusoids part of a molecular complex in plasma? Identifying the nature of such a complex might suggest new opportunities for intervention. Understanding the mechanisms by which LPS is taken up by hepatic sinusoidal cells (via phagocytosed neutrophils and/or platelets? via which surface receptors?) and catabolized in the liver (by AOAH?) might also reveal ways to prevent harmful cytokine production within the systemic compartment. The ability of augmented LPS deacylation and/or dephosphorylation (by alkaline phosphatases?) to limit systemic responses to Gram-negative bacterial infection should be rigorously tested. Understanding how regulatory hormones modulate cytokine production in the liver could suggest new strategies for intervention in infected patients.
CONCLUSIONS
Endotoxin is but one of many microbial molecules that can elicit both protective and harmful responses in animals. It is the best-studied of these molecules, however, and understanding how it is sensed and detoxified may provide a useful framework for considering how animals react to other microbial ligands. The literature reviewed here suggests that:
1. Endotoxin recognition and detoxification mechanisms are normally organized in place and time. At local sites of infection, LPS recognition triggers, and is followed by, the appearance of local detoxifying mechanisms. In contrast, endotoxindetoxifying mechanisms are constitutively present in the blood, where they may limit interactions between endotoxin and circulating cells. Within the systemic compartment, endotoxin sensing occurs principally in reticulo-endothelial organs, especially the liver, and is modulated by neuroendocrine mechanisms. 2. All of the known systemic endotoxin-detoxifying phenomena increase in response to injury, infection and other stresses. 3. Although the endotoxin-detoxifying mechanisms in the systemic compartment may be unable to prevent intravascular inflammatory reactions in patients with high-level bacteremia and/or endotoxemia (such as fulminant meningococcemia), they are probably sufficient to prevent responses to lower amounts of endotoxin that appear in the blood of already-sick patients. This may account for the inconsistent correlation of blood endotoxin levels with clinical outcome in studies of septic patients and the small incremental benefit observed for therapies intended to neutralize endotoxin in the blood. 4. The overall response to endotoxin is determined not only by the mechanisms that allow sensitive and relatively specific recognition of lipid A, but also by the numerous phenomena that shape and limit the intensity and duration of endotoxin sensing and the responses to it. Host defenses based on other microbial molecular 'patterns' doubtless share this dual requirement for sensing and detoxification. Integration of innate immune mechanisms assures microbial killing while preventing self-destruction.
